IKBKB Gene Polymorphism (Single Nucleotide Polymorphism) (SNP) in Psoriatic and Psoriatic Arthritis Patients

Sponsor
South Valley University
Study ID
NCT06729463
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
16 Years - 60 Years
Healthy Volunteers
Accepted

Interventions

  • Humira — DRUG
    Assess the pharmacogenetic association between IKBKB gene polymorphism (SNPs) in psoriatic patients taking systemic biologic therapy

Study Details

Psoriasis is a chronic inflammatory skin disease characterized by scaly indurated erythema. It impairs patients' quality of life enormously. Psoriasis refers to a persistent inflammatory illness of the skin and joints. It also impacts roughly 2%-3% of the inhabitants of the universe

Key Dates

Start date
Dec 1, 2024
Status verified
Dec 2024
Primary completion
Mar 1, 2025
Completion
Mar 30, 2025

Study Design

Enrollment
50 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Group A: Humira Group
    About 20 patients suffering from psoriasis disease and they will take Humira vials about 40 mg every two weeks by subcutaneous injection for 3 months
  • Active Comparator: Group B: Cosentyx Group
    About 20 patients suffering from severe psoriasis will take Cosentyx vials by intravenous infusion as : 1-Loading dose about(300 mg) then decreasing the dose to be 150 mg every month for 3 months.
  • Placebo Comparator: Group C: control Group
    About 10 Healthy participants and will take no medical treatment

Primary Outcome Measure

Treatment of the Psoriasis disease [ Time Frame: 3 months ]

Related Studies